MALAT1 is upregulated by Sp1 and Sp3 and downregulated by MIT (Sp1 binding inhibitor), indicating a possibility of targeting MALAT1 in HCC patients by MIT [43]. This evidence concerns the gene MALAT1 and hepatocellular carcinoma.